Literature DB >> 17912752

Novel mutation in KCNA1 causes episodic ataxia with paroxysmal dyspnea.

Steven J Shook1, Hafsa Mamsa, Joanna C Jen, Robert W Baloh, Lan Zhou.   

Abstract

Episodic ataxia type 1 (EA1) is an autosomal-dominant neurological disease caused by point mutations in the potassium channel-encoding gene KCNA1. It is characterized by attacks of ataxia and continuous myokymia. Respiratory muscle involvement has not been previously reported in EA1. We clinically evaluated a family with features of EA1 and paroxysmal shortness of breath. Coding and flanking intronic regions of KCNA1 were sequenced. We identified a novel 3-nucleotide deletion mutation in KCNA1 in the affected individuals. Our findings of a deletion mutation with unusual respiratory muscle involvement expand the genetic and clinical spectrum of EA1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17912752     DOI: 10.1002/mus.20904

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  15 in total

Review 1.  The Clinical Spectrum of Autosomal-Dominant Episodic Ataxias.

Authors:  Stefan Kipfer; Michael Strupp
Journal:  Mov Disord Clin Pract       Date:  2014-07-28

2.  A de novo KCNA1 Mutation in a Patient with Tetany and Hypomagnesemia.

Authors:  Jenny van der Wijst; Martin Konrad; Sjoerd A J Verkaart; Marcin Tkaczyk; Femke Latta; Janine Altmüller; Holger Thiele; Bodo Beck; Karl Peter Schlingmann; Jeroen H F de Baaij
Journal:  Nephron       Date:  2018-05-23       Impact factor: 2.847

Review 3.  Mutational consequences of aberrant ion channels in neurological disorders.

Authors:  Dhiraj Kumar; Rashmi K Ambasta; Pravir Kumar
Journal:  J Membr Biol       Date:  2014-08-14       Impact factor: 1.843

4.  Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1.

Authors:  Pawel Tacik; Kimberly J Guthrie; Audrey J Strongosky; Daniel F Broderick; Douglas L Riegert-Johnson; Sha Tang; Dima El-Khechen; Alexander S Parker; Owen A Ross; Zbigniew K Wszolek
Journal:  Mayo Clin Proc       Date:  2015-02-03       Impact factor: 7.616

Review 5.  Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration.

Authors:  Niyathi Hegde Shah; Elias Aizenman
Journal:  Transl Stroke Res       Date:  2013-11-19       Impact factor: 6.829

6.  Functional analysis of the Kv1.1 N255D mutation associated with autosomal dominant hypomagnesemia.

Authors:  Jenny van der Wijst; Bob Glaudemans; Hanka Venselaar; Anil V Nair; Anna-Lena Forst; Joost G J Hoenderop; René J M Bindels
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

7.  Mutations in KCND3 cause spinocerebellar ataxia type 22.

Authors:  Yi-Chung Lee; Alexandra Durr; Karen Majczenko; Yen-Hua Huang; Yu-Chao Liu; Cheng-Chang Lien; Pei-Chien Tsai; Yaeko Ichikawa; Jun Goto; Marie-Lorraine Monin; Jun Z Li; Ming-Yi Chung; Emeline Mundwiller; Vikram Shakkottai; Tze-Tze Liu; Christelle Tesson; Yi-Chun Lu; Alexis Brice; Shoji Tsuji; Margit Burmeister; Giovanni Stevanin; Bing-Wen Soong
Journal:  Ann Neurol       Date:  2012-12       Impact factor: 10.422

8.  A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia.

Authors:  Bob Glaudemans; Jenny van der Wijst; Rosana H Scola; Paulo J Lorenzoni; Angelien Heister; Annemiete W van der Kemp; Nine V Knoers; Joost G Hoenderop; René J Bindels
Journal:  J Clin Invest       Date:  2009-03-23       Impact factor: 14.808

9.  Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation.

Authors:  Tracey D Graves; Yoon-Hee Cha; Angelika F Hahn; Richard Barohn; Mohammed K Salajegheh; Robert C Griggs; Brian N Bundy; Joanna C Jen; Robert W Baloh; Michael G Hanna
Journal:  Brain       Date:  2014-02-26       Impact factor: 13.501

Review 10.  New insights into the pathogenesis and therapeutics of episodic ataxia type 1.

Authors:  Maria Cristina D'Adamo; Sonia Hasan; Luca Guglielmi; Ilenio Servettini; Marta Cenciarini; Luigi Catacuzzeno; Fabio Franciolini
Journal:  Front Cell Neurosci       Date:  2015-08-19       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.